0001209191-17-006370.txt : 20170131
0001209191-17-006370.hdr.sgml : 20170131
20170131162447
ACCESSION NUMBER: 0001209191-17-006370
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170130
FILED AS OF DATE: 20170131
DATE AS OF CHANGE: 20170131
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CELGENE CORP /DE/
CENTRAL INDEX KEY: 0000816284
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 222711928
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
BUSINESS PHONE: (908)673-9000
MAIL ADDRESS:
STREET 1: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PEHL MICHAEL F.
CENTRAL INDEX KEY: 0001677939
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34912
FILM NUMBER: 17561439
MAIL ADDRESS:
STREET 1: C/O CELGENE CORPORATION
STREET 2: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-01-30
0
0000816284
CELGENE CORP /DE/
CELG
0001677939
PEHL MICHAEL F.
C/O CELGENE CORPORATION
86 MORRIS AVENUE
SUMMIT
NJ
07901
0
1
0
0
See remarks
Stock Option (right to buy)
113.18
2017-01-30
4
A
0
5000
A
2027-01-30
Common Stock
5000
5000
D
Option is immediately exercisable and will vest in four equal annual installments commencing on January 30, 2018.
The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015).
President, Hematology & Oncology
/s/ Peter N. Kellogg, Attorney-in-Fact
2017-01-31